Piflufolastat (18F)

• Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both? Pending
  2024-511104-16-00 Phase II 1 country Turku University Hospital
• A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting
  2025-521859-23-00 Phase I/II 4 countries Novartis Pharma AG
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617… Recruiting
  2022-502956-29-00 Phase III 11 countries Novartis Pharma AG
• 99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging, PROSTAM… Recruiting
  2024-516083-28-00 Phase II/III 1 country Turku University Hospital
• Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P… Ended
  2024-518171-59-00 Phase III/IV 1 country Canisius Wilhelmina Ziekenhuis
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended
  2022-501343-33-00 Phase III 14 countries Bayer AG; Bayer Consumer Care AG
• A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie… Ended
  2022-501493-19-00 Phase III 3 countries Curium Pet France

Showing 1–7 of 7 trials